The interplay between ABC transporters, microRNAs, and the NRF2 signalling pathway presents a promising avenue for enhancing therapeutic strategies against ovarian cancer, particularly in the context of drug resistance. This evidence concerns the gene NFE2L2 and ovarian carcinoma.